



EFFECTS OF BISMUTH OXIDE 
NANOPARTICLES, CISPLATIN AND 
BAICALEIN-RICH FRACTION FROM Oroxylum 




















EFFECTS OF BISMUTH OXIDE 
NANOPARTICLES, CISPLATIN AND 
BAICALEIN-RICH FRACTION FROM Oroxylum 





NOOR NABILAH BINTI TALIK SISIN 
 
 
Thesis submitted in fulfillment of the requirements 
for the degree of  












Alhamdulillah for His endless blessings and strengths. 
 
This thesis is dedicated to my supportive Ummi Hajjah Azimah, Ayah Haji Talib 
and my whole beloved family. 
 
Deepest gratefulness to my inspiring supervisor and co-supervisors: Dr. Wan 
Nordiana Wan Abd Rahman, Prof. Dr. Khairunisak Abdul Razak and Dr. Nor 
Fazila Che Mat. 
 
This work was also supported by Universiti Sains Malaysia Research University 
Grant (RUI: 1001/PPSK/8012212), using the special facilities from the Nuclear 
Medicine, Radiotherapy and Oncology Department, Hospital USM, the Central 
Research Laboratory, School of Medical Sciences, USM, and the International 
Institute for Halal Research and Training, IIUM. 
 
Appreciations to the helpful Hospital USM staffs (Kak Tie and En. Reduan) and 
PPSK’s postgraduate friends. 
 
Lastly, special thankfulness to my awesome research groupmates: Kak Jo, Kak 





TABLE OF CONTENT 
 
ACKNOWLEDGEMENT .................................................................................. ii 
TABLE OF CONTENT ..................................................................................... iii 
LIST OF TABLES .............................................................................................. x 
LIST OF FIGURES .......................................................................................... xii 
LIST OF ACRONYMS, ABBREVIATIONS AND SYMBOLS .................... xix 
ABSTRAK ..................................................................................................... xxvi 
ABSTRACT ................................................................................................... xxix 
CHAPTER 1 INTRODUCTION ........................................................................ 1 
1.1 Introduction to Radiotherapy ..................................................................... 1 
1.2 Radiosensitization Mechanisms ................................................................ 3 
1.2.1 Physical Phase ............................................................................. 3 
1.2.2 Chemical Phase ........................................................................... 5 
1.2.3 Biological Phase .......................................................................... 7 
1.3 Nanotechnology and Nanomedicine .......................................................... 8 
1.4 Natural Compounds for Anti-Cancer Treatment ..................................... 11 
1.5 Problem Statement and Rationale of the Study ....................................... 13 
1.6 Objectives of the Study ............................................................................ 17 
1.7 Thesis Outline .......................................................................................... 18 
1.8 Research Scopes ...................................................................................... 19 
CHAPTER 2 LITERATURE REVIEW ........................................................... 21 
2.1 Overview on Breast Cancers ................................................................... 21 
2.2 The R’s of Radiobiological Principles ..................................................... 25 





2.2.2 The Fifth R: Radiosensitivity (Intrinsic) ................................... 28 
2.2.3 Additional 6th of the Rs ............................................................. 30 
2.3 Cell Survival Curves Fitted to Linear-Quadratic (LQ) Model ................ 31 
2.4 Radiosensitizers in Radiotherapy ............................................................ 33 
2.4.1 Application of High-Z Metallic Nanoparticles as Radiosensitizers
 ................................................................................................... 34 
2.4.2 Application of Anti-cancer Drugs ............................................. 39 
2.4.3 Application of Natural Compounds........................................... 47 
2.5 Molecular Characterization of Radiosensitization Effects ...................... 53 
2.5.1 Reactive Oxygen Species (ROS) ............................................... 53 
2.5.2 Apoptosis ................................................................................... 57 
2.5.3 Biochemical Changes Analysis by Raman Spectroscopy (RS) . 60 
CHAPTER 3 MATERIALS AND METHODS ................................................ 64 
3.1 Materials Used in the Study ..................................................................... 64 
3.1.1 Reagents and Materials.............................................................. 64 
3.1.2 Equipments ................................................................................ 65 
3.1.3 Software ..................................................................................... 66 
3.2 Methodology of the Study ....................................................................... 66 
3.3 Preparation of Treatment Components .................................................... 67 
3.3.1 Preparation of Bismuth Oxide Nanoparticles (BiONPs) ........... 67 
3.3.2 Preparation of Cisplatin (Cis) .................................................... 70 
3.3.3 Preparation of Baicalein-Rich Fraction (BRF) .......................... 71 
3.4 Cell Culture Protocols.............................................................................. 72 
3.5 Cytotoxicity Tests using PrestoBlue assay .............................................. 74 




3.5.2 Cytotoxicity of Cis .................................................................... 76 
3.5.3 Cytotoxicity of BRF .................................................................. 77 
3.6 Reactive Oxygen Species (ROS) Measurement against BiONPs............ 78 
3.7 Cellular Uptake and Localization of BiONPs in Cells ............................ 79 
3.7.1 BiONPs Intracellular Localization Observation by Microscopy
 ................................................................................................... 79 
3.7.2 BiONPs Cellular Uptake by Flow Cytometry ........................... 80 
3.8 Cell Samples Irradiation Set Up .............................................................. 82 
3.8.1 Treatment Components ............................................................. 82 
3.8.2 High Dose Rate (HDR) Brachytherapy (192Ir of γ-radiation) .... 83 
3.8.3 Megavoltage Photon Beam Therapy ......................................... 84 
3.8.4 Megavoltage Electron Beam Therapy ....................................... 85 
3.9 Post-irradiation Clonogenic Assay .......................................................... 86 
3.10 Cell Survival Analysis and Radiosensitization Effects measurement ..... 87 
3.11 Combination Treatments Analysis of Synergism/Antagonism ............... 88 
3.12 Theoretical Dose Enhancement Factor Calculation ................................ 89 
3.13 Post-irradiation ROS Measurement ......................................................... 91 
3.14 Apoptosis Assay using MuseTM Flow Cytometry ................................... 92 
3.15 Raman Spectroscopic Analysis................................................................ 94 
3.16 Statistical Analysis................................................................................... 97 
CHAPTER 4 RESULTS ................................................................................... 98 
4.1 Cytotoxicity of BiONPs, Cis and BRF – Individually ............................ 98 
4.1.1 Cell Viability against BiONPs................................................... 98 
4.1.2 ROS Production against BiONPs ............................................ 104 




4.1.4 Cell Viability against BRF ...................................................... 109 
4.2 Cellular Uptake and Localization of BiONPs in Cells .......................... 111 
4.2.1 Flow Cytometry Analysis ........................................................ 111 
4.2.2 Microscopy Analysis ............................................................... 113 
4.3 Cells Survival Curves and Sensitization Enhancement Ratio (SER) .... 114 
4.3.1 Individual Treatment Components .......................................... 114 
4.3.1 (a) 192Ir of γ-radiation ................................................. 114 
4.3.1 (b) Photon Beam Therapy .......................................... 116 
4.3.1 (c) Electron Beam Therapy ........................................ 118 
4.3.2 Combinatorial Treatment Components ................................... 121 
4.3.2 (a) 192Ir of γ-radiation ................................................. 121 
4.3.2 (b) Photon Beam Therapy .......................................... 123 
4.3.2 (c) Electron Beam Therapy ........................................ 125 
4.3.3 Combinatorial Treatment Analysis of Synergism/Antagonism
 ................................................................................................. 128 
4.3.3 (a) 192Ir of γ-radiation ................................................. 129 
4.3.3 (b) Photon Beam Therapy .......................................... 130 
4.3.3 (c) Electron Beam Therapy ........................................ 131 
4.4 Theoretical DEF Estimations ................................................................. 134 
4.4.1 Theoretical DEF versus Experimental SER ............................ 136 
4.5 Post-irradiation ROS Measurement ....................................................... 138 
4.5.1 Individual Treatment Components .......................................... 138 
4.5.1 (a) 192Ir of γ-radiation ................................................. 138 
4.5.1 (b) Photon Beam Therapy .......................................... 139 




4.5.2 Combinatorial Treatment Components ................................... 142 
4.5.2 (a) 192Ir of γ-radiation ................................................. 142 
4.5.2 (b) Photon Beam Therapy .......................................... 143 
4.5.2 (c) Electron Beam Therapy ........................................ 144 
4.5.3 Influence of Time on ROS Generation .................................... 146 
4.5.3 (a) 192Ir of γ-radiation ................................................. 146 
4.5.3 (b) Photon Beam Therapy .......................................... 147 
4.5.3 (c) Electron Beam Therapy ........................................ 148 
4.5.4 Influence of Beams Quality for BC Combination on ROS 
Generation ............................................................................... 149 
4.6 Apoptosis Analysis of BC Combination for 192Ir of γ-radiation............ 150 
4.7 Raman Spectroscopic Analysis of BC Combination for 192Ir Source of Γ-
radiation with the 192Ir source ................................................................ 158 
CHAPTER 5 DISCUSSIONS ......................................................................... 164 
5.1 Cytotoxicity of BiONPs, Cis and BRF – Individually .......................... 164 
5.1.1 Cell Viability against BiONPs................................................. 164 
5.1.2 ROS Production against BiONPs ............................................ 168 
5.1.3 Cell Viability against Cis......................................................... 172 
5.1.4 Cell Viability against BRF ...................................................... 173 
5.2 Cellular Uptake and Localization of BiONPs in Cells .......................... 175 
5.3 Radiosensitization Effects ..................................................................... 179 
5.3.1 Double Combination of Individual BiONPs, Cis or BRF with 
Radiation.................................................................................. 179 
5.3.1 (a) BiONPs and Radiation.......................................... 179 




5.3.1 (c) BRF and Radiation ............................................... 187 
5.3.2 Combination of BC, BB or BCB with Radiation .................... 190 
5.3.3 Synergism, Additive or Antagonism (of Combination 
Treatments) .............................................................................. 195 
5.4 Theoretical DEF vs. Experimental SER ................................................ 199 
5.5 ROS Measurement Post-irradiation ....................................................... 202 
5.5.1 Individual Treatment Components .......................................... 203 
5.5.2 Combination Treatment Components...................................... 208 
5.5.3 Influence of Time on ROS Generation .................................... 211 
5.5.4 Influence of Beams Quality on ROS Generation in BC 
Combination ............................................................................ 212 
5.6 Apoptosis Mechanism in MCF-7 Cells after BC Combination and 192Ir of 
γ-radiation Treatment............................................................................. 213 
5.7 Biochemical Changes of MCF-7 Cells after BC Combination and 192Ir of 
γ-radiation Treatment............................................................................. 217 
CHAPTER 6 CONCLUSION ......................................................................... 224 
6.1 Summary of the Findings ...................................................................... 224 
6.1.1 Cytotoxicity of Individual Components: BiONPs, Cis and BRF
 ................................................................................................. 224 
6.1.2 Radiosensitization Effects of Individual and Combination 
Treatments ............................................................................... 224 
6.1.3 ROS Measurement Post-irradiation ......................................... 225 
6.1.4 Apoptosis ................................................................................. 226 
6.1.5 Subcellular Biochemical Changes using Raman Spectroscopic 




6.2 Future Directions ................................................................................... 226 
REFERENCES ................................................................................................ 228 
APPENDICES .................................................................................................... 1 
APPENDIX A: BiONPs DILUTIONS ............................................................. 1 
APPENDIX B: CIS MAIN STOCK CALCULATION ................................... 2 
APPENDIX C: BRF CONCENTRATION CALCULATION FOR 
CYTOTOXICITY ASSAY .................................................... 3 
APPENDIX D: R2 VALUES OF EACH SURVIVAL CURVES BASED ON 
LQ MODEL ............................................................................ 4 
APPENDIX E: COMPUSYN SOFTWARE PROTOCOL ............................. 7 
APPENDIX F: COMBINATION INDEX (CI) FOR THE ACTUAL 
EXPERIMENTAL POINTS ................................................... 9 
APPENDIX G: RAMAN SPECTRAL DATA PRE-PROCESSING .............. 1 
APPENDIX H: STATISTICAL TESTS FOR BEAM QUALITY ROS 
MEASUREMENT .................................................................. 1 
APPENDIX I: STATISTICAL TESTS FOR APOPTOSIS DATA ............... 1 
APPENDIX J: FOLD CHANGES OF APOPTOTIC INDEX ....................... 3 
APPENDIX K: TURNITIN REPORT ............................................................. 1 






LIST OF TABLES 
 
Table 2:1 Clinical categories of breast cancers ......................................... 23 
Table 2:2 Types of breast cancers lines used in pre-clinical studies ......... 24 
Table 2:3  Radiosensitization studies on Bi complexes in the current decade
 ................................................................................................... 38 
Table 2:4  IC50 values of cisplatin on several breast cancer cell lines. ....... 43 
Table 2:5  Examples of ROS inducers involved in cancer treatments ....... 55 
Table 3:1 Different weight of Bi(NO3)3.5H2O and NaOH would influence 
the BiONPs sizes to be yielded ................................................. 70 
Table 3:2 Dilution techniques for the Cis final concentrations. ................ 76 
Table 3:3 Treatment components for radiosensitization effect and ROS 
measurement studies. ................................................................. 83 
Table 3:4 Calculated Zeff for individual component. ................................. 90 
Table 4:1 Radiobiological analysis based on LQ models for Ir-192 of γ-
radiation corresponding to Figure 4.12. .................................. 116 
Table 4:2 Radiobiological analysis based on LQ models for photon beam 
therapy corresponding to Figure 4.13 ...................................... 118 
Table 4:3 Radiobiological analysis based on LQ models for electron beam 
therapy corresponding to Figure 4.14 ...................................... 120 
Table 4:4 Overall results of SER values by Individual Components ...... 121 
Table 4:5 Radiobiological analysis based on LQ models for Ir-192 of γ-
radiation corresponding to Figure 4.15 ................................... 123 
Table 4:6 Radiobiological analysis based on LQ models for photon beam 
therapy corresponding to Figure 4.16 ...................................... 125 
Table 4:7 Radiobiological analysis based on LQ models for electron beam 
therapy corresponding to Figure 4.17 ...................................... 127 
Table 4:8 Overall results of SER values by Combinatorial Treatments .. 128 
Table 4:9 The overall averages of CI values which are the indication of 
synergism (less than 0.9), additive (0.9 to 1.2), and antagonism 
(more than 1.2) effects ............................................................. 133 
Table 4:10 Theoretical DEF values at 0.38 MeV and 2.0 MeV estimated from 
the Figure 4.21. The percentages were the ratio to the total volume 
in the cell suspensions. ............................................................ 136 
Table 4:11 Stages of apoptosis after 14 hours treatment for the treatment of 
BC combination with Ir-192 of γ-radiation corresponding to 





Table 4:12 Stages of apoptosis after 40 hours treatment for the treatment of 
BC combination with Ir-192 of γ-radiation corresponding to 
Figure 4.36 ............................................................................... 157 
Table 4:13 Detected peaks corresponded to Figure 4.38 and Figure 4.39. 162 
Table 4:14 Assignment of Raman spectral peaks, based on the results 
reported in the literature and the present work, corresponding to 





LIST OF FIGURES 
 
Figure 1.1 The current principles of radiobiology (Boustani et al., 2019; 
Chew et al., 2021; Cui, 2016; IAEA, 2017; Kesarwani et al., 
2018; Mallick et al., 2020; Mayadev et al., 2017; “R,” 2017; 
Ramroth, 2017; Wray & Lightsey, 2016; Zoiopoulou, 2020). .... 7 
Figure 1.2 Shapes of nanomaterials in the form of (A) dendrites, (B) cubes, 
(C) stars, (D) triangles, (E) cylinders and (F) spheres. Images are 
adapted from several published studies (Gratton et al., 2008; Lee 
et al., 2019; Muhammad et al., 2018; Xie et al., 2017). ............ 10 
Figure 1.3 Classical radiosensitization process in the presence of therapeutic 
NPs in RT for cancer treatment. The figure is adapted from Yan 
Liu et al. (2018). ........................................................................ 11 
Figure 2.1 Stages of breast cancers according to the tumor sizes. Illustration 
was adapted from Breast Cancer Now Ltd. (2018) ................... 22 
Figure 2.2 The typical surviving curves fitted to the LQ model indicated the 
chronic line (for normal cells) and acute line (for cancer cells). 
The picture is taken from Mayadev et al. (2017). ..................... 32 
Figure 2.3  The surviving curves fitted to LQ model depicts the areas of one-
hit event (α component) two-hit event event (β component). The 
dotted line shows the α /β ratio line. The graph is taken from 
McMahon & Prise (2019). ......................................................... 33 
Figure 2.4 The energies of the incident photon (hʋ) are fully absorbed by the 
NPs at the low energies, and partially absorbed by the NPs at the 
high energies. The electrons (e-) released by the interactions 
would induce DNA damages to the cells. ................................. 35 
Figure 2.5 Leaves of the OI plant ............................................................... 49 
Figure 2.6 Regulation of genes and proteins expression (increase in red 
bubbles, decrease in blue bubbles) in cancer cells after treatment 
with OI plant extract or baicalein, leading to the disruption of the 
cell cycle as well as metastasis and finally causing autophagic or 
apoptotic cell death. ................................................................... 52 
Figure 2.7 Morphological changes of cells in apoptosis processes after 
treatments, which involved the six characteristics, referred to 
IAEA (2017) and K. K. Jain (2008). ......................................... 58 
Figure 3.1 The brief flow chart of the research methodology. The study into 
three phases, such as biocompatibility, radiosensitization and 
mechanism of action studies. ..................................................... 67 
Figure 3.2 Flow processes of the BiONPs synthesis. The protocols were 
reported in previous literatures (Zainal Abidin, 2019; Zulkifli, 





Figure 3.3 (A) The stirring of the dilution of Bi(NO3)3.5H2O and Na2SO4 in 
distilled water (B) The yellow precipitate resultants in Schott 
bottle sealed for hydrothermal reaction. .................................... 69 
Figure 3.4 The processes of obtaining BRF from OI plant leaves, referred to  
Wahab and Mat (2018). ............................................................. 71 
Figure 3.5 Images of the three cell lines that were used in this study, fixed 
using cold methanol and stained with 1% of crystal violet 
solution. ..................................................................................... 73 
Figure 3.6 Calculation of BiONPs stock solution. ...................................... 74 
Figure 3.7 The method to measure the intracellular ROS generation. 
Protocols were modified from Yan Li et al. (2010) and Hui Yang 
et al. (2009). ............................................................................... 79 
Figure 3.8 Protocol developed in the present study for the BiONPs 
intracellular localization for observation under the light 
microscope. ................................................................................ 80 
Figure 3.9 Quantitative measurement of BiONPs cellular uptake by flow 
cytometry, referred to Reineke (2012). ..................................... 81 
Figure 3.10 Set up for Ir-192 of γ-radiation with (A) upper view and (B) 
lateral view. (C) The connection between the HDR machine to 
the surface mold on the table couch. (D) Schematic diagram of 
the set up. ................................................................................... 84 
Figure 3.11 Set up of irradiation in (A) real view and (B) schematic diagram 
for the photon beam therapy. ..................................................... 85 
Figure 3.12 Set up of irradiation in (A) real view and (B) schematic diagram 
for the electron beam therapy with an applicator. ..................... 86 
Figure 3.13 The arrangement for the irradiations in 6-wells plates involved 
row A which was reserved for control cells and row B which was 
reserved for the BC treatment component in triplicates. ........... 93 
Figure 3.14 The MuseTM Cell Analyzer used for apoptosis assay. ............... 93 
Figure 3.15 (A) Renishaw InVia Raman Microscope was used for this study. 
(B) Glass coverslips with cells attached were put on a borosilicate 
float glass microscope slide with aluminium metal coating under 
microscope lens, as shown by the red arrow. ............................ 96 
Figure 3.16 The schematic diagram of the point of analysis using Raman 
Microscope, which was centered at the nucleoli of the cell. ..... 96 
Figure 4.1 Cell viabilities after treatment with BiONPs of 60 nm diameter 
size with five concentrations for 24, 48 and 72 hours on MCF-7, 
MDA-MB-231 and NIH/3T3 cell lines, respectively. The dashed 
lines marked 80% of the cell viability. Each error bar represents 
the standard error of the mean (SEM). ...................................... 99 
Figure 4.2 Cell viabilities after treatment with BiONPs of 70 nm diameter 
size with five concentrations for 24, 48 and 72 hours on MCF-7, 




lines marked 80% of the cell viability. Each error bar represents 
the SEM. .................................................................................. 100 
Figure 4.3 Cell viabilities after treatment with BiONPs of 80 nm diameter 
size with five concentrations for 24, 48 and 72 hours on MCF-7, 
MDA-MB-231 and NIH/3T3 cell lines, respectively. The dashed 
lines marked 80% of the cell viability. Each error bar represents 
the SEM. .................................................................................. 102 
Figure 4.4 Cell viabilities after treatment with BiONPs of 90 nm diameter 
size with five concentrations for 24, 48 and 72 hours on MCF-7, 
MDA-MB-231 and NIH/3T3 cell lines, respectively. The dashed 
lines marked 80% of the cell viability. Each error bar represents 
the SEM. .................................................................................. 103 
Figure 4.5 Detection of DCF percentages after treatment with four different 
BiONPs sizes (60, 70, 80 and 90 nm) of the 0.5 mM of BiONPs 
immediately after treatment (0-1 h), 3.5, 6 and 24 hours in MCF-
7, MDA-MB-231 and NIH/3T3 cell lines respectively. The 
treated cells were compared to control cells treated with DCH2F-
DA only (positive control), 100 % DCF fluorescent. Each error 
bar represents the SEM, but in this figure they are too small. . 105 
Figure 4.6 Detection of DCF percentages after treatment with five 
concentrations of the BiONPs of 60 nm diameter size 
immediately after treatment (0-1 h), 3.5, 6 and 24 hours in MCF-
7, MDA-MB-231 and NIH/3T3 cell lines respectively. The 
treated cells were compared to control cells treated with DCH2F-
DA only (positive control), 100% DCF fluorescent. Each error 
bar represents the SEM. ........................................................... 107 
Figure 4.7 Colour changes of the culture media at 4 hours after adding the 
Prestoblue reagent to the cells in the wells. The arrangement of 
Cis or BRF treatment in the 96 wells plate started with C as the 
control row and followed by the treatments on cells with the 
highest concentration (1) to the lowest concentration (9). ...... 108 
Figure 4.8 Cis cytotoxic evaluation against MCF-7, MDA-MB-231, and 
NIH/3T3 cell lines. Each point shows the average percentage of 
viable cells in comparison to the negative control. The dashed 
lines represent the IC25 and IC50 levels, respectively. Curves are 
fitted using the Dose-Response model. Error bars represent the 
SEM. ........................................................................................ 109 
Figure 4.9 Cytotoxic evaluation of BRF against MCF-7, MDA-MB-231, and 
NIH/3T3 cell lines. Each point shows the average percentage of 
viable cells in comparison to the negative control. Dashed lines 
represent the IC25 and IC50 levels. Curves are fitted using the 
Dose-Response model. Error bars represent the SEM. ........... 110 
Figure 4.10 Cell population detected by flow cytometric analysis on MCF-7, 
MDA-MB-231 and NIH/3T3 cell lines after the introduction of 
the 60 nm of BiONPs with 0.5 mM concentration, relative to the 
control. Each percentage represent the average of triplicate 




Figure 4.11 Localization of BiONPs close to nuclei in the (A) MCF-7, (B) 
MDA-MB-231 and (C) NIH/3T3 cells, after 24 hours incubation 
with the BiONPs. Arrows indicated the rod-shaped BiONPs 
presented in the cells. The scale of each picture is 20 µm. ..... 113 
Figure 4.12 The cell survival curves of the MCF-7, MDA-MB-231 and 
NIH/3T3 cell lines after Ir-192 of γ-radiation at 0 to 4 Gy of doses 
in the presence of BiONPs (red line), Cis (blue line), BRF (green 
line) and the control (black line). The survival data were fitted to 
LQ models. Error bars represent the standards errors of survival 
fractions. .................................................................................. 115 
Figure 4.13 The cell survival curves of the MCF-7, MDA-MB-231 and 
NIH/3T3 cell lines after photon beam therapy at 0 to 10 Gy of 
doses in the presence of BiONPs (red line), Cis (blue line), BRF 
(green line) and the control (black line). The survival data were 
fitted to LQ models. Error bars represent the standards errors of 
survival fractions. .................................................................... 117 
Figure 4.14 The cell survival curves of the MCF-7, MDA-MB-231 and 
NIH/3T3 cell lines after electron beam therapy at 0 to 10 Gy of 
doses in the presence of BiONPs (red line), Cis (blue line), BRF 
(green line) and the control (black line). The survival data were 
fitted to LQ models. Error bars represent the standards errors of 
survival fractions. .................................................................... 119 
Figure 4.15 The cell survival curves of the MCF-7, MDA-MB-231 and 
NIH/3T3 cell lines after Ir-192 of γ-radiation at 0 to 4 Gy of doses 
in the presence of BC (red line), BB (blue line), BCB (green line) 
and the control (black line). The survival data were fitted to LQ 
models. Error bars represent the standards errors of survival 
fractions. .................................................................................. 122 
Figure 4.16 The cell survival curves of the MCF-7, MDA-MB-231 and 
NIH/3T3 cell lines after photon beam therapy at 0 to 10 Gy of 
doses in the presence of BC (red line), BB (blue line), BCB (green 
line) and the control (black line). The survival data were fitted to 
LQ models. Error bars represent the standards errors of survival 
fractions. .................................................................................. 124 
Figure 4.17 The cell survival curves of the MCF-7, MDA-MB-231 and 
NIH/3T3 cell lines after electron beam therapy at 0 to 10 Gy of 
doses in the presence of BC (red line), BB (blue line), BCB (green 
line) and the control (black line). The survival data were fitted to 
LQ models. Error bars represent the standards errors of survival 
fractions. .................................................................................. 126 
Figure 4.18 The Fa-CI plots of BC (blue), BB (red), and BCB (green) 
combination treatments in MCF-7, MDA-MB-231 and NIH/3T3 
cells for γ-radiation with the Ir-192 source. Each point is the CI 
values of the actual combination data point, and the lines are the 
simulated CI values. ................................................................ 130 
Figure 4.19 The Fa-CI plots of BC (blue), BB (red), and BCB (green) 




cells for photon beam therapy. Each point is the CI values of the 
actual combination data point, and the lines are the simulated CI 
values ....................................................................................... 131 
Figure 4.20 The Fa-CI plots of BC (blue), BB (red), and BCB (green) 
combination treatments in MCF-7, MDA-MB-231 and NIH/3T3 
cells for electron beam therapy. Each point is the CI values of the 
actual combination data point, and the lines are the simulated CI 
values. ...................................................................................... 132 
Figure 4.21 Theoretical DEF of each treatment component (BiONPs, Cis, 
BRF, BC, BB and BCB) at (A) various energy ranges, (B) Ir-192 
of γ-radiation average energy of 0.38 MeV, and (C) 6 MV photon 
beam with an effective energy of 2 MeV. The percentage of each 
component depended on the volume of the treatment components 
used during the irradiation. ...................................................... 135 
Figure 4.22 Comparison of theoretical DEF values and experimental SER 
values by each treatment component for Ir-192 of γ-radiation in 
MCF-7, MDA-MB-231, and NIH/3T3 cells. Theoretical DEF 
values are obtained from Table 4:10, and experimental SER 
values are acquired from Table 4:4 and Table 4:8. ................. 137 
Figure 4.23 Comparison of theoretical DEF values and experimental SER 
values by each treatment component for photon beam therapy in 
MCF-7, MDA-MB-231, and NIH/3T3 cells. Theoretical DEF 
values are obtained from Table 4:10, and experimental SER 
values are acquired from Table 4:4 and Table 4:8. ................. 138 
Figure 4.24 Percentage of ROS generation immediately after (0 hour) the γ-
radiation with the Ir-192 source at doses of 0, 3 and 6 Gy in MCF-
7, MDA-MB-231, and NIH/3T3 cell lines treated with BiONPs, 
BRF and Cis. Error bars represent the SEM. ........................... 139 
Figure 4.25 Percentage of ROS generation immediately after (0 hour) the 
photon beam irradiation at doses of 0, 3 and 6 Gy in MCF-7, 
MDA-MB-231, and NIH/3T3 cell lines treated with BiONPs, 
BRF and Cis. The y-axis scale of ROS Generation (%) of 
NIH/3T3 cell graph differed from the graphs of MCF-7 and 
MDA-MB-231 cells. Error bars represent the SEM. ............... 140 
Figure 4.26 Percentage of ROS generation immediately after (0 hour) the 
electron beam irradiation at doses of 0, 3 and 6 Gy in MCF-7, 
MDA-MB-231, and NIH/3T3 cell lines treated with BiONPs, 
BRF and Cis. The y-axis scale of ROS Generation (%) of 
NIH/3T3 cell graph differed from the graphs of MCF-7 and 
MDA-MB-231 cells. Error bars represent the SEM. ............... 141 
Figure 4.27 Percentage of ROS generation immediately after (0 hour) γ-
radiation with the Ir-192 source at doses of 0, 3 and 6 Gy in MCF-
7, MDA-MB-231, and NIH/3T3 cell lines treated with BC, BB, 
and BCB combinations. Error bars represent the SEM. .......... 142 
Figure 4.28 Percentage of ROS generation immediately after (0 hour) the 




MDA-MB-231, and NIH/3T3 cell lines treated with BC, BB, and 
BCB combinations. The y-axis scale of ROS Generation (%) of 
NIH/3T3 cell graph differed from the graphs of MCF-7 and 
MDA-MB-231 cells. Error bars represent the SEM. ............... 143 
Figure 4.29 Percentage of ROS generation immediately after (0 hour) the 
electron beam irradiation at doses of 0, 3 and 6 Gy in MCF-7, 
MDA-MB-231, and NIH/3T3 cell lines treated with BC, BB, and 
BCB combinations. The y-axis scale of ROS Generation (%) of 
NIH/3T3 cell graph differed from the graphs of MCF-7 and 
MDA-MB-231 cells. Error bars represent the SEM. ............... 145 
Figure 4.30 Percentage of ROS generation increments immediately after (0 
h), 3 hours and 24 hours after γ-radiation with the Ir-192 source 
with only a dose of 6 Gy in MCF-7, MDA-MB-231, and NIH/3T3 
cell which were treated with the BiONPs, BRF, Cis, BC, BB, and 
BCB, relative to the positive control. Error bars represent the 
SEM. ........................................................................................ 147 
Figure 4.31 Percentage of ROS generation increments immediately after (0 
h), 3 hours and 24 hours after photon beam therapy with only a 
dose of 6 Gy in MCF-7, MDA-MB-231, and NIH/3T3 cell which 
were treated with the BiONPs, BRF, Cis, BC, BB, and BCB, 
relative to the positive control. The y-axis scale of ROS 
Generation (%) of NIH/3T3 cell graph differed from the graphs 
of MCF-7 and MDA-MB-231 cells.  Error bars represent the 
SEM. ........................................................................................ 148 
Figure 4.32 Percentage of ROS generation increments immediately after (0 
h), 3 hours and 24 hours after electron beam therapy with only a 
dose of 6 Gy in MCF-7, MDA-MB-231, and NIH/3T3 cell which 
were treated with the BiONPs, BRF, Cis, BC, BB, and BCB, 
relative to the positive control. Error bars represent the SEM. 149 
Figure 4.33 A review of the percentages of ROS generation in the presence of 
BC combination for all the radiation beams. Error bars represent 
the SEM. .................................................................................. 150 
Figure 4.34 Overall cell population profile detected by flow cytometric 
analysis on MCF-7 cells of control and BC treatment after 14 
hours (14h) and 40 hours (40h) of Ir-192 of γ-radiation 
irradiation. Each box is gated by cell size index and Annexin V 
agent detections. ...................................................................... 152 
Figure 4.35 Apoptosis profile from the flow cytometric analysis on MCF-7 
cells of control (left column) and BC combination treatment (right 
column) after 14 hours of γ-radiation with the Ir-192 source with 
doses of 0, 2 and 4 Gy. Each box is gated by cell viability (7-
AAD) agent and Annexin V agent detections. The percentages in 
the figure represent one sample only, but the average percentage 
of the three samples is tabulated in Table 4:11. ...................... 153 
Figure 4.36 Apoptosis profile from the flow cytometric analysis on MCF-7 
cells of control (left column) and BC combination treatment (right 




doses of 0, 2 and 4 Gy. Each box is gated by cell viability (7-
AAD) agent and Annexin V agent detections. The percentages in 
the figure represent one sample only, but the average percentage 
of the three samples is tabulated in Table 4:12 ....................... 156 
Figure 4.37 Label-free imaging by Raman microscopy of control and BC-
treated MCF-7 cells fixed at 0- and 24-hours after γ-radiation with 
the Ir-192 source, with the nucleoli as the region of interests at 
the center for analysis. White arrows indicate the BiONPs 
presence in the cells, while yellow arrows show the cellular 
membrane damages. The scales of each picture are 20 µm. ... 158 
Figure 4.38 Average Raman spectrum of about three single MCF-7 cells 
immediately after (0 hour) γ-radiation with the Ir-192 source with 
doses of 0, 0.5 and 2 Gy for control (dashed lines) and BC 
combination treatment (solid lines). The labels refer to the 
wavenumber value and attribution of the most critical spectral 
features. The zoomed-in area ranged from 1100 to 1300 cm-1.
 ................................................................................................. 160 
Figure 4.39 Average Raman spectrum of about three single MCF-7 cells at 24 
hours γ-radiation with the Ir-192 source with doses of 0, 0.5 and 
2 Gy for control (dashed lines) and BC combination treatment 
(solid lines). The labels refer to the wavenumber value and 
attribution of the most critical spectral features. The zoomed-in 
area ranged from 1100 to 1300 cm-1........................................ 161 
Figure 5.1 The structural changes in cells detected by Raman spectroscopic 







LIST OF ACRONYMS, ABBREVIATIONS AND SYMBOLS 
 
% Percent 
°C Degree Celsius 
µ Micro 
•OH Hydroxyl radicals 
103Pd Palladium-103  
125I Iodine-125  
137Cs Cesium-137 
169Yb Ytterbium-169 
192Ir or Ir-192 Iridium-192  
2D 2-dimentional 
3D 3-dimentional 
5-ALA 5-Aminolevulinic acid  
60Co Cobalt-60 
7-AAD 7-aminoactinomycin D 
AMPK  5' adenosine monophosphate-activated protein kinase 
ATP Adenosine triphosphate 




Bcl2 B-cell lymphoma 2 
Bi Bismuth 




Bi2O3 Bismuth oxide  
Bi2S3 Bismuth sulfide 
Bi2Se3 Bismuth selenide 
BiFeO3 Bismuth ferrite 
BiONPs Bismuth oxide nanoparticles 
BiP5W30 Bismuth heteropoly tungstate 
BRF Baicalein-rich fraction 
C Carbon 
CDK Cyclin-dependent kinase 
CI Combination index 
Cis Cisplatin 
CK2 Casein kinase 2 
cm Centimeter 
CO2 Carbon dioxide 
CRT Chemoradiotherapy 
CT Computed tomography 
Cyt Cytosine 
DCF 2',7'-dichlorofluorescein 
DCH2F-DA 2',7'- dichlorodihydro-fluorescein diacetate 
DCIS Ductal carcinoma in situ 
DEF Dose enhancement factor 
DIABLO Direct IAP Binding protein with Low pi 
dmax Depth of maximum dose 
DMEM Dulbecco’s Modified Eagles Medium  




DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
Drp1 Dynamin-related protein 1 
EMT Epithelial‑mesenchymal transition 
ER Estrogen receptor 
ERK Extracellular receptor kinases 
Fa Fraction affected 
FA Folic acid 
Fas Fas cell surface death receptor 
FasL Fas ligand 
FBS Fetal bovine serum  
G1 phase Growth phase 1 
G2 phase Growth phase 2 
G3BP1  GTPase-activating protein-binding protein 
GI50 Concentration which induced 50% of growth inhibition 
GLP Ganoderma lucidum polysaccharide 
GPx Glutathione peroxidase 
GSK-3β Glycogen synthase kinase 3β 
GTP Guanosine triphosphate 
Gy Gray (unit of radiation dose) 
H Hydrogen 
H2O2 Hydrogen peroxide 
HDR High dose rate 
HER2 Human epidermal growth factor receptor 2 




HIF Hypoxia-inducible factor 
HO-1 Heme oxygenase-1 
HRS Hormone receptor sensitive 
IAEA International Atomic Energy Agency 
IARC International Agency for Research on Cancer 
IC25 Inhibition concentration which causes 25% cell death 
IC50 Inhibition concentration which causes 50% cell death 
IL Interleukin 
JNK c-Jun NH2-terminal kinase 
kV Kilovoltage 
kVp Kilovoltage peak 
LET Linear energy transfer 
LQ Linear quadratic 
M phase Mitosis phase 
MAPKs Mitogen-activated protein kinases 
MeV Mega electron-volt 
ml Millimeter 
mMol/L Milli mol per liter 
mM Millimolar 
MMP Matrix metalloproteinase 
MNCR Malaysia National Cancer Registry 
MONPs Metal oxide NPs 
mRNA Messenger RNA 
MT Multitarget 




MTT 3- [4,5-dimethylthiazol-2- yl]-2,5-diphenyl tetrazolium bromide 
MV Megavoltage 
Na2SO4 Sodium sulphate 
NaOH Sodium hydroxide 
NCI National Cancer Institute 
NF-κB Nuclear factor kappa B 
NIH National Institute of Health 
nm Nanometer 
NOX Nicotinamide adenine dinucleotide phosphate oxidase 
NPC Nuclear pore complex 
NPs Nanoparticles 
Nrf nuclear factor E2-related factor 2  
O2•− Superoxide radicals 
OI Oroxylum indicum 
p53 Protein 53 
PARP Poly-ADP-ribose polymerase 
PBS Phosphate buffered saline 
PEG Polyethylene glycol 
Phe Phenylalanine 
PO2
- Phosphodioxy bond of phosphate 
PR Progesterone receptor  
pRb Retinoblastoma protein 
PTP1B protein tyrosine phosphatase 1B 
Q Quadrant 




RBE Relative biological effectiveness 
RCR Repairable conditionally repairable 
redox Reduction-oxidation 
RNA Ribonucleic acid 
ROS Reactive oxygen species 
RS Raman spectroscopy 
RT Radiotherapy 
S phase DNA synthesis phase 
SEM Standard error of the mean 
SER Sensitization enhancement ratio 
SESN Sestrins 
SF Survival fraction 
SLC Solute carries 
SLD Sublethal damage 
SMAC Mitochondria-derived activator of caspase 
SNHG Small nucleolar RNA host gene 
SOD Superoxide dismutase 
SPIONs Superparamagnetic iron oxide NPs 
SSD Source-to-surface distance 
STAT3 Signal transducer and activator of transcription 3 
TLC Thin layer chromatography 
TNF Tumor necrosis factor 
TRAF2 Tumor necrosis factor receptor-associated factor 2  





WHO World Health Organization 
XIAP X-linked inhibitor of apoptosis protein 
Z Atomic number 
ZEB1-AS1 Zinc finger E-box binding homeobox 1 antisense 1  














KESAN RADIOSENSITIVITI BERPENSINERGI DARIPADA GABUNGAN 
NANOPARTIKEL BISMUT OKSIDA, CISPLATIN DAN FRAKSI KAYA-




Strategi multimod bagi rawatan kanser bertujuan untuk menghapuskan 
penyakit barah yang kompleks dengan menggunakan peningkatan hasil terapi melalui 
efek gabungan berbanding dengan teknik berasingan yang mungkin mempunyai 
beberapa had. Ubat kemoterapi seperti cisplatin dapat meningkatkan dos sinaran pada 
tisu sasaran. Walau bagaimanapun, ketoksikan ubat-ubatan komersil telah mendorong 
para penyelidik untuk mencari agen alternatif dan pemeka sinaran tanpa toksin, 
kemungkinan daripada derivatif semula jadi atau nanopartikel (NPs) yang berasaskan 
logam. Kajian ini bertujuan untuk menyelidik kesan radiosensitiviti sinergi oleh NPs 
bismut oksida (BiONPs), cisplatin (Cis) dan fraksi kaya-baicalein (BRF) daripada 
ekstrak daun Oroxylum indicum (OI) di bawah radioterapi klinikal menggunakan 
brakiterapi dengan kadar dos tinggi (HDR), pancaran foton, dan pancaran elektron. 
Kesitotoksikan, pengambilan ke dalam sel, dan pengeluaran spesies oksigen reaktif 
(ROS) yang disebabkan oleh BiONPs dikaji ke atas sel kanser payudara MCF-7 dan 
MDA-MB-231 serta sel normal fibroblas NIH/3T3 bagi menerangkan kebolehgunaan 
BiONPs dalam aplikasi radioterapi. Kepekatan Cis dan BRF yang selamat juga telah 
ditentukan sebelum iridiasi. Pengkuantitian kesan radiosensitiviti dan penjanaan ROS 
dikaji dengan BiONP, Cis, dan BRF individu, serta kombinasi BiONPs-Cis (BC), 
BiONPs-BRF (BB) dan BiONPs-Cis-BRF (BCB) bagi brakiterapi HDR, pancaran 




untuk menjelaskan perubahan biokimia subselular dan mekanisma kematian sel. Hasil 
kesitotoksikan menunjukkan bahawa BiONPs telah menyebabkan kematian sel yang 
minimum kurang daripada 20% secara purata, sementara nilai pengeluaran ROS oleh 
BiONPs boleh diabaikan. Peningkatan pengambilan NPs ke dalam sel menunjukkan 
bahawa BiONPs boleh disebatikan dan juga melekat pada permukaan sel. Demikian 
itu, didapati bahawa 0.5 mM dari 60 nm BiONPs adalah kepekatan dan saiz optima 
untuk aplikasi radioterapi. Nilai terendah bagi 25% kepekatan perencatan oleh 
individu Cis dan BRF yang diperoleh adalah masing-masing 1.30 µM dan 0.76 µg/ml, 
dan nilai ini digunakan untuk eksperimen seterusnya. Siasatan kesan radiosensitiviti 
antara komponen-komponen rawatan menunjukkan nilai nisbah peningkatan 
sensitiviti (SER) tertinggi adalah menggunakan gabungan BC dalam sel MCF-7, 
diikuti oleh rawatan BCB dan BB. Kesannya lebih ketara untuk brakiterapi HDR 
berbanding pancaran foton dan elektron. Sementara itu, rawatan gabungan telah 
menyebabkan tahap ROS yang lebih tinggi untuk pancaran foton berbanding 
brakiterapi dan pancaran elektron. Peningkatan ROS tertinggi adalah disebabkan oleh 
gabungan BC dalam sel MDA-MB-231. Menariknya, gabungan BCB juga 
memberikan nilai SER yang tinggi tetapi secara kolektifnya turut mempengaruhi sel 
normal. Gabungan BC dalam sel MCF-7 telah menunjukkan potensi sebagai pemeka 
sinaran yang berkesan untuk brakiterapi dengan kejadian proses apoptosis awal, 
terutamanya dalam masa 40 jam selepas radiasi. Penemuan dari spektroskopi Raman 
menunjukkan bahawa gabungan BC dan brakiterapi akan mempengaruhi proses 
glikolisis, susunan struktur asid amino dan kestabilan DNA/RNA yang menyarankan 
peningkatan kesan radiasi pada sel-sel kanser. Kesimpulannya, kajian ini 
menunjukkan potensi BiONP, Cis dan BRF sebagai pemeka sinaran yang dapat 




pemeka sinaran yang poten ini mungkin dapat menghasilkan kesan sinergi yang akan 





SYNERGETIC RADIOSENSITIZATION EFFECTS OF BISMUTH OXIDE 
NANOPARTICLES, CISPLATIN AND BAICALEIN-RICH FRACTION 




Multimodal strategies of cancer treatment aim to eradicate complex malignant 
disease with enhanced therapeutic outcome with combined synergetic effects in 
contrast to individual techniques that might exhibits some limitations. 
Chemotherapeutic drug such as cisplatin have been applied to increase radiation doses 
at target tissues in radiotherapy. However, commercial chemo-drugs toxicities had 
compelled the researchers to evaluate alternatives for non-toxic agents and 
radiosensitizers, potentially from natural derivatives or metal-based nanoparticles 
(NPs). Integration of novel nanomaterials and natural product as radiosensitizer to 
increase the anti-tumors efficacy are also promising to enhance the treatment 
performance. This study aimed to investigate the synergetic radiosensitization effects 
of bismuth oxide NPs (BiONPs), cisplatin (Cis) and a baicalein-rich fraction (BRF) 
from Oroxylum indicum (OI) leaves extract under clinical radiotherapy of High Dose 
Rate (HDR) brachytherapy, photon, and electron beams. The cytotoxicity, cellular 
uptake, and reactive oxygen species (ROS) generation induced by BiONPs were 
initially investigated on MCF-7 and MDA-MB-231 breast cancer as well as NIH/3T3 
normal fibroblast cell lines in elucidating the BiONPs feasibility for radiotherapy 
application. The safe concentration of Cis and BRF were also determined prior 
irradiation. Quantification of radiosensitization effects and ROS generation were 




BiONPs-BRF (BB) and BiONPs-Cis-BRF (BCB) combinations for High Dose Rate 
(HDR) brachytherapy, photon, and electron beams. Raman Spectroscopy and 
apoptosis analysis were conducted to elucidate the subcellular biochemical changes 
and cells death mechanism. The cytotoxicity results provide that the BiONPs induced 
minimal cell deaths constituting less than 20% on average while ROS production by 
BiONPs was negligible. The increment of NPs cellular uptake indicated that BiONPs 
were internalized and bound to the cellular surfaces. Consequently, 0.5 mM of 60 nm 
BiONPs was found to be an optimum concentration and size for radiotherapy 
application. The lowest values of the 25% of inhibition concentration by individual 
Cis and BRF obtained were 1.30 µM and 0.76 µg/ml, respectively, and utilized for the 
subsequent experiments. Investigation of the radiosensitization effects among the 
treatment components indicated the highest SER value by BC combination in MCF-7 
cells, followed by BCB and BB treatments. The effects were more prominent for Ir-
192 of γ-radiation compared to photon and electron beams. Meanwhile, the 
combination treatments present the higher ROS levels for photon beam than 
brachytherapy and electron beam. The highest ROS enhancement was attributed to the 
presence of BC combination in MDA-MB-231 cells. Interestingly, the BCB 
combination also showed a high SER but collaterally affected the normal cells. The 
BC combination of MCF-7 cells showed potential as an effective radiosensitizer for 
brachytherapy with the early apoptosis predominantly occurred within 40 hours after 
irradiation. Finally, the finding from Raman spectroscopy demonstrated that the 
BiONPs-Cis and brachytherapy combination would affect the glycolysis process, the 
amino acid structure arrangement and the DNA/RNA stability that would suggest the 
enhancement of radiation effects on cancer cells. In conclusion, this study suggests the 




of radiotherapy to eradicate the cancer cells. The combination of these potent 
radiosensitizers could produce synergetic effects that will elevate the therapeutic 







1.1 Introduction to Radiotherapy 
Radiotherapy (RT) is one of the cancer treatments, apart from surgery, 
chemotherapy, immunotherapy, hormone therapy, targeted therapy, stem cell 
transplant and precision medicine, as listed by the International Agency for Research 
on Cancer (IARC) and the National Cancer Institute (NCI) (IARC, 2014; NCI, 2020). 
The International Atomic Energy Agency (IAEA) also stated that RT can be 
administered alone or in combination with chemotherapy, as well as after surgery in 
the cancer treatment plans (IAEA, 2017). RT uses high energy ionizing radiation to 
manage and treat cancer diseases as well as some other non-malignant conditions (“R,” 
2017). Nowadays, there are approximately 7600 RT centers around the world (IAEA, 
2017). Meanwhile in Malaysia, there are currently 30 RT centers with approximately 
58 megavoltage machines, in several states such as Federal Territory of Kuala Lumpur, 
Feral Territory of Putrajaya, Selangor, Kelantan, Sarawak, Sabah, Perak, Penang, 
Malacca and Negeri Sembilan (Yahya et al., 2019).  
Ionizing radiation started to be used as a therapy in cancer care since Curie's 
discovery of radium by 1898 and its successful treatment on cervical cancer in 1905, 
which was the foundation for brachytherapy (IAEA, 2017). Later, the external beam 
source was standardized in 1976 for clinical RT practice (IAEA, 2017). There are two 
major types of RT available which are the external beam therapy (electron or photon 
beams) and the internal therapy (brachytherapy) (NCI, 2020). 
The external beam is generated from a megavoltage (MV) machine known as 




teletherapy machine (IAEA, 2017). The MV machine uses a current of fast traveling 
subatomic particles that were formed by electricity or high-frequency electromagnetic 
waves, creating the high energy of electron radiation. (IAEA, 2017; Khan, 2014).  In 
addition, the X-ray photon beam could also be supplied from the linac via 
Bremsstrahlung phenomena, a braking process which deflects the electrons from the 
original path (Khan, 2014; “Radiation in Bioanalysis Spectroscopic Techniques and 
Theoretical Methods,” 2019). The linac has a gantry which could operate at a 360-
degree rotation to deliver the radiations to a targeted body part from many directions 
(IAEA, 2017; NCI, 2020). The photon and electron beams are used in RT for cancers 
in different positions. Electron beam with energies up to 21 MeV is usually used for 
superficial tumors, while the photon beam is used for deep-seated tumors (Abidin, 
Zulkifli, et al., 2019; Raizulnasuha Ab Rashid et al., 2017; Wilkens, 2007).  
In contrast, brachytherapy is a highly localized treatment in which radioactive 
sources are delivered near to the target sites internally, thus providing a high dose of 
gamma (γ)-energy radiation to the cancer cells while conserving electrical energy 
(IAEA, 2017; Wan Nordiana Wan Abdul Rahman, 2010). Originally, radon dan 
radium sources were used for the brachytherapy, but nowadays, the common isotopes 
that are used included Cesium-137 (137Cs), Iridium-192 (192Ir or Ir-192), Gold-198 
(198Au), Iodine-125 (125I), and Palladium-103 (103Pd) (Khan, 2014). The physical 
properties of the radionuclides also offer some advantages relative to the external 
beams, in terms of source size, γ-energy, source half-life, and flexibility (Khan, 2014). 
The brachytherapy is usually utilized for the treatment of prostate cancer and 






1.2 Radiosensitization Mechanisms 
Irrespective of the types of radiation, the mechanism of cell death after ionizing 
radiation involved a sequential physical, chemical, and biological effects (Brun & 
Sicard-Roselli, 2016). Firstly, physical interactions between the radiation and matters, 
concerning the energy absorption, were initiated in a few femtoseconds (McMahon & 
Prise, 2019; Mondelaers & Lahorte, 2001). After that, the chemical process occurred 
for a few nanoseconds, comprised of the energy transfer and reactions among the 
radiation-induced chemicals and some biological intermediates (McMahon & Prise, 
2019; Mondelaers & Lahorte, 2001). The afterward short- and long-term biological 
responses that could pertain for hours, days, weeks or years after the radiation exposure 
would modify the cellular and tissue mechanisms (McMahon & Prise, 2019; 
Mondelaers & Lahorte, 2001). 
 
1.2.1 Physical Phase 
The physical phase is an interval period in which the high-energy particles pass 
through the target medium and instigate the energy absorption as well as the ionization 
or excitation of the matter (Cui, 2016; Mondelaers & Lahorte, 2001). The high-energy 
particles may consist of neutrons, and photons from X-rays and γ-radiation, as well as 
charged particles (electron, α- and β-particles) (Mondelaers & Lahorte, 2001). The 
high-energy charged particles are termed as direct ionizing particles as it can be 
considered as primary irradiation itself (Mondelaers & Lahorte, 2001). Meanwhile, the 
photons and neutrons were considered as indirect ionizing radiations due to the 




The high energy radiation will be absorbed and transferred to non-bonding or 
π-bonding atomic electrons of the other elements such as oxygen and nitrogen or other 
compounds (Mondelaers & Lahorte, 2001). The process can be measured as linear 
energy transfer (LET), in which the energy lost per length of the particles’ track and 
absorbed in the medium (Mallick et al., 2020; Zeman et al., 2016). The LET level 
depends on the medium density, as well as the types and velocity of the primary 
radiation (Mondelaers & Lahorte, 2001). Neutrons and heavy ions are the high LET 
radiations, while X-rays and electrons are the low LET radiations (Zeman et al., 2016). 
High LET radiations will stimulate a high amount of excitation and ionizations per 
unit of tissue traversed, which also linearly proportional to relative biological 
effectiveness (RBE) and the number of cell killed (IAEA, 2017).  
In this phase, the physical enhancement could also happen. It is defined as the 
boost of the electrons energy that were released back from the other matter present, 
such as nanoparticles, after the absorption (T. Guo, 2019). The physical enhancement, 
for instance from a few eV to tens of keV, could be calculated by comparing the energy 
deposition in the samples with nanomaterials relative to the samples without it (T. Guo, 
2019). The energy from the secondary electrons released from the nanomaterials 
would be deposited back in the surrounding medium, usually in the forms of reactive 
oxygen species (ROS) molecules (T. Guo, 2019).  
In the presence of metallic nanoparticles (NPs), interactions with the ionizing 
radiations will result in Compton effects, X-ray fluorescence, pair production process, 
photoelectric interactions, or Auger electron emission  (Howard et al., 2020). 
Theoretically, these interactions were influenced by the NPs’ atomic numbers (Z) and 
sizes, as well as the amount of incident radiation energy (Ahmad et al., 2020; Howard 




generate a higher mass-energy absorption coefficient between the NPs and the cells or 
tissues (Ahmad et al., 2020).  
The physical differences in ionizing radiation exposure, energy deposition and 
the energy released would lead to different subsequent chemical and biological effects 
(McMahon & Prise, 2019). High LET radiations would densely accumulate the energy 
in the cells and tissues, increasing the ROS production and producing more DNA 
damages (Howard et al., 2020; McMahon & Prise, 2019). While the NPs are also 
involved in the physical mechanism, its presence is insufficient to cause damages to 
the cells, indicating the importance of other possible chemical and biological 
mechanisms (Howard et al., 2020). 
 
1.2.2 Chemical Phase 
Chemical bonds among the atoms and molecules have low energy similar to 
the quanta of non-ionizing radiation, which could be overpowered by the higher energy 
of ionizing radiations and promoted the ionization of many molecules of the cells, 
tissues and medium (Mondelaers & Lahorte, 2001). Byproducts of the ionization is the 
generation of ROS, which includes both radical and non-radical species. The ROS was 
generated due to the breakage of the chemical bonds of tissue molecules, especially 
the water molecules, after the irradiation (IAEA, 2017; Hui Wang, Jiang, Van De 
Gucht, et al., 2019).  
The radical reactions encompass two contrary responses, which are pro-
oxidative and scavenging reactions (Cui, 2016; Mondelaers & Lahorte, 2001). 
Scavenging reactions describe the acts of deactivating the free radicals by some 
reducing biomolecules agents such as thiol-containing molecules through 




Mondelaers & Lahorte, 2001). Meanwhile, pro-oxidative reactions define the 
encounter of radicals with other biological molecules to produce other radicals by 
addition or abstraction of radicals, which may lead to further impairments of the cells 
and tissue components (Cui, 2016; Mondelaers & Lahorte, 2001). The chemical 
modifiers involved in the responses, such as oxygen would trigger superoxide radicals 
(O2•−), hydrogen peroxide (H2O2) and hydroxyl radicals (•OH) (Cui, 2016; P. Ma et 
al., 2017; “R,” 2017; Zeman et al., 2016).  
Both opposite reactions simultaneously occurred during the nanoseconds of 
post-irradiation, forming a wide range of byproducts. In the end, the robust ionization 
processes would yield excited molecules, electrons, ions and free radicals in the 
irradiated system, regardless of the type of the radiation (Mondelaers & Lahorte, 
2001). In the presence of matters such as gases, liquids or solids during irradiation, 
surplus free radicals reactions are stimulated (Mondelaers & Lahorte, 2001). The 
chemical responses are faster in gases and liquids, compared to the solid matter such 
as the NPs, which could be detected even months after irradiation (Mondelaers & 
Lahorte, 2001). 
The increment of the effects which were caused by catalysis processes due to 
the chemical properties of the nanomaterials is termed as the chemical enhancement 
(T. Guo, 2019). The enhancement is divided into two types including a slight ROS 
changes and more reaction of interest occurred owing to the catalysis by the surface of 
the NPs, as well as a high elevation of ROS level with or without the absorption of the 
radiation by the NPs (T. Guo, 2019). Following the induction of the high amount of 
ROS, it could initiate the cell apoptosis and cell cycle redistribution (Alan Mitteer et 





1.2.3 Biological Phase 
Biological pathways are the most slow-acting processes compared to the 
physical and chemical phases, involving a complex molecular chain of reactions within 
both normal and cancer cells at the target sites of RT (McMahon & Prise, 2019). The 
clinical routine of RT encompasses fractionated irradiations, in which total doses of 
irradiation were divided and delivered in smaller doses over several weeks (Ray et al., 
2015). The gold standard for the RT is that a total of 70 Gy given by 2 Gy over several 
weeks, and it corresponds to the four Rs principles of radiobiology, as such repair, 
reoxygenation, redistribution, and repopulation (IAEA, 2017; “R,” 2017; Wray & 
Lightsey, 2016). Nowadays, there are two additional Rs for the principles of 
radiobiology, which are radiosensitization and reactivation of antitumor immune 
responses (Boustani et al., 2019; Cui, 2016; Mayadev et al., 2017). The principles, as 
illustrated in Figure 1.1, were crucial in understanding the cause and effects of 
fractionated irradiation dose treatment on the normal and cancer cells. Further 
literature on the R's of radiobiology would be stated in Section 2.2.  
 
 
Figure 1.1 The current principles of radiobiology (Boustani et al., 2019; Chew et 
al., 2021; Cui, 2016; IAEA, 2017; Kesarwani et al., 2018; Mallick et al., 
2020; Mayadev et al., 2017; “R,” 2017; Ramroth, 2017; Wray & 




1.3 Nanotechnology and Nanomedicine  
Materials in nanometer scales have long existed in our nature. However, only 
recently that systems and technologies have advanced towards nanoscales application 
in many fields, including medicine. In medical aspects, many areas have begun to use 
the nanotechnologies, such as nanogenomics, nanomolecular diagnostics, 
nanoproteomics, nanopharmaceuticals, nano-arrays, nanofluidics, and NPs (K. K. Jain, 
2008). The contributions of nanotechnology in the medical field for prevention, 
diagnostics, and treatments of diseases were termed as nanomedicine. Nanomedicine 
hugely plays a role in health sciences, especially in drug delivery, tissue engineering, 
magnetic resonance imaging, cancer therapy, tissue repair, and cellular therapy (Alarifi 
et al., 2014; Cui, 2016). 
The evolution of nanomedicine started approximately a century ago on the 
discovery of sugar molecules' size of 1 nm by Einstein, and from then on, there were 
more inventions for nano-sized molecular analysis and visualization (K. K. Jain, 
2008). From the limited resolution of conventional light microscopy, there is scanning 
X-ray microscopy, which could measure down to 10 nm molecules (K. K. Jain, 2008). 
Electron microscopy, near-infrared laser microscopy, confocal laser microscopy, 
fluorescence microscopy, atomic force microscopy and combinations of the 
microscopy techniques enable the researchers to determine the physical structures of 
the biomolecules before and after the respective treatments with super imaging 
resolution and 3-dimensional reconstruction (K. K. Jain, 2008). Nanotechnology was 
highly beneficial in medical areas as the sizes of the cell biology fundamental features 





The nanoscale visualization of cellular biology had advanced to integrate 
nanotechnology into the treatment of diseases by targeting the nanometer 
biomolecules. For examples, the nanomaterials were utilized in delivering drugs to the 
targeted sites, promoting regeneration of cells, engineering tissue scaffolds, protecting 
the healthy sites from free-radicals damages as well as stimulating antibacterial, 
antiviral and anti-cancer properties (K. K. Jain, 2008; B. Kumar & Smita, 2016). The 
tissue engineering and tissue regeneration nanotechnology were highly valued in 
reconstructive surgery treatments (K. Amin et al., 2019; Drouet & Rey, 2020; 
Mohammadi Nasr et al., 2020; Walsh et al., 2019). Additionally, silver, gold and silica 
NPs could increase the free radicals production for the toxicity effects towards cancer 
cells, whereas selenium and cerium oxide NPs could assist the reduction-oxidation 
(redox) balance by anti-inflammatory and anti-oxidant mechanisms (P. Ghosh et al., 
2015; Hirst et al., 2009; Peidang Liu et al., 2019; Misawa & Takahashi, 2011; Passagne 
et al., 2012). Current chemotherapy research also designated that several types of drugs 
such as paclitaxel, doxorubicin and cisplatin could be delivered by or co-delivered with 
metallic-, drug-, or polymeric-based NPs for the better effects (J. Deng, Xun, et al., 
2018; X. L. Guo et al., 2019; W. Wang et al., 2015).  
NPs are one of the nanobiotechnology classifications (K. K. Jain, 2008). The 
NPs are defined as an aggregation of matter with a radius of not more than 100 nm 
(Bhushan, 2010). There are several kinds of NPs that could be synthesized such as 
inorganic-based (metallic, magnetic, quantum dots),  polymeric-based (synthetic, 
natural, hybrid), and lipid-based NPs (Aliofkhazraei, 2015). Moreover, the various 
methods of NPs synthesis would yield different shapes of the NPs, for instance, the 
shape of rods, stars, spheres, triangles, dendrites, ellipsoids, cubes, and cylinders 




Muhammad et al., 2018; Xie et al., 2017). Some of the shapes are depicted in Figure 
1.2.  
 
Figure 1.2 Shapes of nanomaterials in the form of (A) dendrites, (B) cubes, (C) 
stars, (D) triangles, (E) cylinders and (F) spheres. Images are adapted 
from several published studies (Gratton et al., 2008; Lee et al., 2019; 
Muhammad et al., 2018; Xie et al., 2017). 
 
The application of therapeutic NPs is the growing trend in the research of RT 
cancer treatment, in which the NPs with high atomic numbers (Z) are extensively being 
investigated for their excellent radiosensitization effects. RT is the most common type 
of curative and palliative treatment for most of cancer patients (IAEA, 2017; Martins 
et al., 2018). High dose of radiation in eliminating cancer cells usually affected the 
surrounding healthy tissue and induced several complications (Bingya Liu et al., 
2015). The presence of matters called radiosensitizers, such as the NPs, in a tumor 
would help local absorption of the radiation energy and concentrate more dose at the 
target site, and thus contributed to the DNA damage of the cancer cells (Wan Nordiana 
Rahman et al., 2014). Figure 1.3 simplified the mechanism of actions involved in the 





Figure 1.3 Classical radiosensitization process in the presence of therapeutic NPs 
in RT for cancer treatment. The figure is adapted from Yan Liu et al. 
(2018). 
 
1.4 Natural Compounds for Anti-Cancer Treatment 
Since ancient times, plant extracts are commonly used to treat diseases. In 
modern days, this type of treatment is known as complementary medicines (WHO, 
2013). Complementary medicines are classified as the primary sources of health care 
in Africa and as the supportive treatment to chemotherapy in European countries and 
North America (WHO, 2013).  
Plants are the principal sources of medicinal phytochemicals that have the 
potentials to be exploited as a means of cancer therapy (Wahab, 2019). A review 
reported several types of herbs and natural products used by cancer patients in Middle 
Eastern countries, such as garlic, honey, turmeric, black cumin, camel milk, stinging 
nettle, carrot and Arum palaestinum (Ben-Arye et al., 2016). Many other pieces of 
research also validated the anti-cancer and anti-proliferative properties of some plant 




nutans, Trigona laeviceps propolis, Passiflora foetida (henna) and Oroxylum indicum 
(O. indicum; OI) (Baharara et al., 2016; Buranrat, Noiwetch, et al., 2020; Loizzo et al., 
2013; Sisin et al., 2017; Umthong et al., 2011; Yong et al., 2013). 
The medicinal phytochemicals may induce anti-cancer mechanism and cause 
the cancer cell death. Apoptosis is one of the anti-cancer mechanisms exerted by the 
extracts of several plants such as Dillenia suffruticosa, Cordia dichotoma, 
Calophyllum inophyllum fruit, Garcinia mangostana (mangosteen), and  OI in pre-
clinical cancer cells studies (Foo et al., 2016; D. R. N. Kumar et al., 2012; 
Moongkarndi et al., 2004; M. A. Rahman & Hussain, 2015; Shanmugapriya et al., 
2016; Wahab et al., 2019). Exposure of other extracts from Kielmeyera coriacea, 
Coriandrum sativum and OI on several cancer cells had also demonstrated the cell 
cycle arrest actions (Figueiredo et al., 2014; E. L. H. Tang et al., 2013; Zazali et al., 
2013). Other specific anti-proliferative pathways on cancer cells expressed from some 
other plant extracts included the inhibition of protein tyrosine phosphatase 1B 
(PTP1B) and serine-threonine kinase (CK2) which have roles in metabolism and 
cellular proliferation, as well as the disruption of glycogen synthase kinase 3β (GSK-
3β)-modulated mitochondrial binding of enzyme hexokinase II (Y. Guo et al., 2020; 
McCarty et al., 2020; To et al., 2020). 
As the plant sources have such promising effects for cancer treatments, the 
plants’ compounds could possibly potentiate the actions in RT. More plants are being 
investigated for their effects in combination with radiations on cancer cells. In HeLa 
cervical cancer cell line, the extract of Artemisia kopetdaghensis, Kelussia 
odoratissima and Ferula gummosa had suggested their radiosensitization effects of the 
2 Gy dose of γ-radiation from the 60Co units (Fanipakdel et al., 2019; Forouzmand et 




plant, had also demonstrated the high efficacy and radiosensitivity in the head and neck 
cancer cells (Vazifedan et al., 2017). Natural phenolic compounds, such as curcumin 
and sinensetin from citrus, were combined with the RT against breast cancer cells and 
resulted in the enhancement of radiation doses (Minafra et al., 2019; Rezakhani et al., 
2020). There were more cancer cell deaths due to the high expression of p53, STAT3 
and B-cell lymphoma 2 protein (Bcl2) genes (Minafra et al., 2019; Rezakhani et al., 
2020). 
 
1.5 Problem Statement and Rationale of the Study 
Chemotherapy has been combined with the RT procedure to boost the treatment 
performance of certain cancers, and it is termed as chemoradiotherapy (CRT). The 
chemotherapeutic drugs that are usually served as radiosensitizers are cisplatin, 
gemcitabine, and doxorubicin (X. L. Guo et al., 2019; Hashemi et al., 2013). Data from 
clinical studies confirmed the benefits of combined CRT in local tumor control. In 
comparison to irradiation alone, the results of concurrent CRT were shown to boost 
the RT effectiveness (A. Mukherjee et al., 2016). A few clinical studies also proved 
that the effect of the cisplatin in combination with brachytherapy was compelling, and 
the percentage of disease-free survival after one year was more than 70% (Chandel & 
Jain, 2016; Hashemi et al., 2013; A. Mukherjee et al., 2016).  
The biological rationale is that a chemotherapy drug such as cisplatin could act 
as a radiosensitizer that can enhance radiation dose at the tumor site. Therefore, 
treatment could be performed with a lower radiation dose, which will reduce the 
harmful effects on normal cells. The potential benefit of concurrent CRT is, however, 
confined by the risk of complication due to the exposure of healthy organs to high dose 




which inhibit the post-irradiation DNA damage repairs, which could diminish normal 
cells’ survival (Cui, 2016). 
Evidence of survival improvements have been observed, but intrinsic toxicity 
remains a significant issue with concurrent CRT. There are many side consequences 
induced by conventional drugs, such as ototoxicity, low blood cell production, 
menstrual abnormalities, peripheral neuropathy, reproductive problems and the growth 
of other types of cancer (Chemocare.com, 2016). A study by Aghili and co-workers 
on combinatorial of cisplatin and medium dose rate brachytherapy indicated the most 
common side effects were proctitis, leukopenia, cystitis, anemia, vomiting and nausea 
(Mahdi Aghili et al., 2018). 
To widen the therapeutic window of CRT, NPs-based radiosensitizers are 
introduced. In pre-clinical research, a few metallic elements had shown the potential 
to be radiosensitizers, such as gold, superparamagnetic iron oxide, platinum, and 
bismuth NPs (Lazim et al., 2018; Wan Nordiana Rahman et al., 2014; Raizulnasuha 
Abdul Rashid et al., 2019). Bismuth oxide (Bi2O3) NPs (BiONPs) has also been 
investigated as a potential radiosensitizer (C. Stewart et al., 2016; Taha et al., 2018). 
The physical justification is that increase in radiation interaction may occur due to the 
high atomic number of the bismuth element (Z = 83), which could instigate more 
photons absorption and release more electrons even when low radiation energy was 
being used (C. A. C. Stewart, 2014; Taha et al., 2018; Zulkifli, Razak, Rahman, et al., 
2018). In comparison to other types of NPs, the composition of bismuth may trigger 
additional retention, absorption, and scattering of the radiation at the cancer site, and 
thus demonstrated a higher enhancement of the dose (Ovsyannikov et al., 2015; C. A. 
C. Stewart, 2014). A study on radiosensitization of BiONPs, as well as bismuth sulfide, 




enhance the kilovoltage radiation with the BiONPs showed the highest effects 
(Mamdooh Alqathami et al., 2016). GEANT4 was used to simulate brain tissue 
irradiation in the presence of BiONPs, and the dose enhancement factor (DEF) was 
quantified up to 18.55, which presented the promising BiONPs capacities (Taha et al., 
2018).  
Thus, in the present study, BiONPs were selected as the alternative 
radiosensitizer of cisplatin as well as the combination of both components, which may 
potentially enhance the radiation dose through the synergetic effects of both 
compounds. It is anticipated that the radiosensitization effects by combinatorial 
BiONPs and cisplatin (BC) will be better than the results of combinatorial gold NPs 
and cisplatin from another study (Cui, 2016). 
In regards to their attractive biocompatibility profile, the potential of BiONPs 
as radiosensitizer has been investigated in vitro, in vivo as well as in silico and 
phantoms studies which portrayed impressive results (Mamdooh Alqathami et al., 
2016; C. A. C. Stewart, 2014; Taha et al., 2018). However, the research above did not 
investigate the applicability of the BiONPs on breast cancer RT, and this study is the 
first empirical precedent to apply BiONPs for clinical megavoltage beams. 
Due to the toxicity of the commercial synthetic chemo-drugs, researchers started to 
explore the options for the nontoxic chemotherapeutic agent and radiosensitizers, 
possibly from natural chemicals and derivatives are of interest (L. Jiang & Iwahashi, 
2019). Since the attainment of data on phytochemicals and constituents of medicinal 
plants in treating and preventing diseases and cancers, especially breast cancers, are 
significant, it is imperative to discern and identify the active constituents of the plant 
extracts in order to develop new natural-based drugs or medicine (A. Amin et al., 2009; 




et al., 2014; Shanmugapriya et al., 2016; Sisin et al., 2017; To et al., 2020). Oroxylum 
indicum (OI) leaves extract had been validated to have anti-cancer, anti-virus, anti-
oxidant and radiosensitization properties (Wan Nordiana Rahman et al., 2019; Wahab 
& Mat, 2018). OI leaves are also easily available in Malaysia. The used of plant leaves 
as the natural-based medicine would also improve the acceptance of the medicine as 
natural-based agents were expected to have low toxicity in vitro and in vivo 
experiments (Awang et al., 2020; Dinda et al., 2015; I. N. Kang et al., 2019; Wan 
Nordiana Rahman et al., 2019; Wahab & Mat, 2018; Zazali et al., 2013). While OI 
leaves extract to have the radiosensitizing properties, it is still unknown whether a 
newly isolated baicalein-rich fraction (BRF) from the same plant gives the same effects 
due to the different composition of the compounds in the BRF. 
Furthermore, most of the previous works on NPs emphasized the dose 
enhancement by individual NPs as well as a combination with commercial drug only, 
but the present study applied three components: BiONPs, cisplatin (Cis) and BRF as 
the prospective radiosensitizers. This study is the first to evaluate the combination of 
the three components, especially involving the natural compound BRF in combination 
with the BiONPs (BB) or the BiONPs-Cis (BCB) combination, as well as the RT. 
In the cancer treatment, triple drug-based chemotherapy research have been 
clinically proven in improving the cancer responses compared to a combination of two 
drugs (Noronha et al., 2015; Somani et al., 2011). However, each drug has its adverse 
effects, and the act of combining drugs would increase the systemic side effects (Goyal 
et al., 2016). Recently, Kareliotis et al. (2020) reviewed several modern cancer 
therapies strategies and concluded that there are the needs of multimodal treatment 
which required the synergy between the ionizing radiation and sensitizing agents. 




promote anti-cancer effects while reducing toxicity, as well as to combine natural BRF 
with BiONPs (BB) to replace Cis in the BiONPs-Cis (BC) combination. This work 
focused on whether the triple combination of prospective radiosensitizers was more 
successful than the double combination or single radiosensitizer in stimulating ROS 
generation, their interactions and cell survival after the clinical RT. 
 
1.6 Objectives of the Study 
Investigation of the radiosensitization effects of bismuth oxide nanoparticles 
(BiONPs) in combination with cisplatin (Cis) and a baicalein-rich fraction (BRF) from 
Oroxylum indicum leaves for clinical radiotherapy beams. 
 
Specific Objectives: 
1) To determine the cytotoxicity effect of BiONPs, Cis and BRF on MCF-7 and 
MDA-MB-231 breast cancer cells as well as NIH/3T3 normal fibroblast cells. 
2) To investigate the reactive oxygen species (ROS) generation and localization 
of BiONPs within the breast cancer cells and normal fibroblast cells. 
3) To measure the cell survival and ROS with individual BiONPs, Cis and BRF 
and combinatorial BiONPs-Cis (BC), BiONPs-BRF (BB) and BiONPs-Cis-
BRF (BCB) using clinical RT beams (192Ir of γ-rays, 6 MV of photon and 6 
MeV of electron beams). 
4) To radiobiologically evaluate the type of interactions (synergism, additive 
effects or anatagonism) for the radiosensitization effects of 3 individual 
treatments (BiONPs, Cis and BRF) as well as 3 combination treatments (BC, 




5) To analyze the involvement of apoptosis mechanism after treatment exposure, 
with the selected treatment components. 
6) To identify the subcellular biochemical and structural changes using Raman 
spectroscopy after treatment exposure with the selected treatment components.  
 
1.7 Thesis Outline 
There are six chapters in this thesis. 
Chapter 1 is an introduction to the RT, radiosensitization mechanism, 
nanotechnology nanomedicine, as well as natural anti-cancer agents. The problem 
statements and objectives of the study are also explained. 
Chapter 2 articulates the overview of the breast cancers data as one of the focus 
in this study. The application of several kinds of radiosensitizer in RT, such as metallic 
nanoparticles, anti-cancer drugs and natural compounds, were included in this chapter. 
Detailed types of molecular characterization methods of the radiosensitization effects 
were also mentioned. 
Chapter 3 contains specific protocols in preparing the treatment components, 
culturing the cell lines, testing the cytotoxicities of the treatment components, 
measuring the ROS generation, and setting up the irradiation of 192Ir of γ-rays, photon 
and electron beams. This chapter also explained the post-irradiation assay and analysis, 
such as clonogenic assay as well as the analysis of cell survival, combination treatment 
interactions, ROS generation, apoptosis using MuseTM flow cytometry, and subcellular 
changes by Raman spectroscopy. 
Chapter 4 reported the results of the experiments in the study. Based on the 
results of the cytotoxicity of the BiONPs, Cis and BRF, the safe concentrations were 




from the survival curves and compared to the theoretical dose enhancement factor 
(DEF). One of the best combination treatments were selected for the following 
apoptosis and subcellular changes analysis. The results also involved statistical results. 
Chapter 5 explains the findings in the previous chapter, which were supported 
by other previous studies. 
Chapter 6 summarizes the findings and conclusion in a few sentences for each 
part of the study. 
 
1.8 Research Scopes 
This thesis is divided into 3 phases of study. 
Phase 1:  The biocompatibility study of BiONPs, Cis and BRF. 
Phase 2:  The radiosensitization studies of BiONPs, Cis, BRF, BC, BB, and BCB 
treatments. 
Phase 3:  The mechanism of action studies of the selected radiosensitizer 
combination. 
 
The first phase is the part of biocompatibility studies of three types of 
prospective radiosensitizers, which are metallic nanoparticles (BiONPs), commercial 
chemo-drug (Cis), and natural compound from OI plant leaves (BRF). The 
cytotoxicity, cellular uptake, and reactive oxygen species (ROS) generation induced 
by BiONPs were initially investigated 3 cell lines, which were 2 different subtypes of 
breast cancer cell lines (MCF-7 cells and MDA-MB-231 cells) and 1 normal cell line 
(NIH/3T3 cells). The ROS generation by the BiONPs incubation with the cells were 




safe concentration of each individual treatment component was determined as 0.5 mM 
of 60 nm of BiONPs, 1.30 µM of Cis and 0.76 µg/ml of BRF.  
Second phase is the radiosensitization studies of BiONPs, Cis, BRF, BC, BB, 
and BCB treatment components. Quantification of radiosensitization effects and ROS 
generation were conducted for 192Ir of γ-rays, 6 MV of photon beam, and 6 MeV of 
electron beam. The synergetic interactions of the combination treatment and linked to 
the SER values. The experimental SER values were also compared to the calculated 
theoretical DEF values for the monoenergetic beams of 192Ir of γ-rays and 6 MV of 
photon beam. The ROS generation after the treatment exposure were deduced to be 
insignificant and could not predict the survival fractions of the cells. Finally, the 
components that were established to cause the optimum synergetic radiosensitization 
effects are BC combination for the 192Ir of γ-rays on MCF-7 breast cancer cells. 
The last part is the mechanism of action studies of the chosen radiosensitizer 
combinations. Apoptosis analysis for 14 and 40 hours after the exposure of MCF-7 
breast cancer cells to the BC combination and the 0, 2 and 4 Gy of 192Ir of γ-rays to 
enlighten the cells death mechanism. Meanwhile, Raman spectroscopic analysis were 
conducted to elucidate the subcellular biochemical changes after the exposure of MCF-
7 breast cancer cells to the BC combination and the 0, 0.5 and 2 Gy of 192Ir of γ-rays. 
Radiosensitization processes were discovered to occur predominantly due to early 
apoptosis, as well as the involvement of glycogen increment, amino acid 








This chapter presents the reviews on breast cancers, the potential of several types of 
radiosensitizers, such as NPs, drugs and natural compounds, as well as the intricate 
mechanisms which may transpire to result in the radiosensitization effects. 
 
2.1 Overview on Breast Cancers 
Globally, breast cancers had accounted for up to 2 million new cancer cases in 
2018, nearly similar to the number of lung cancers followed by colorectal, prostate and 
stomach cancers (IARC, 2014; WHO, 2019a). The breast cancer is the leading cause 
of death for women in 103 countries (WHO, 2019a). The incidence frequency was the 
highest in Northern and Western Europe, as well as New Zealand and Australia (Bray 
et al., 2018).  
In Malaysia, there were approximately 43 thousand number of new cancer 
cases in 2018, and the breast cancers accounted for up to 7.5 thousand cases of it 
(WHO, 2019b). 32% of the females' cases were also attributable to the breast cancers, 
followed by colorectal cases (12%), cervical cancer (7%), and ovarian cancer (5%) 
(WHO, 2019b). While breast cancer ranked the first as the most frequent new cancer 
cases in Malaysia, it was ranked second for the number of total cancer death which 
come after lung cancer-induced deaths (WHO, 2019b).  
According to the Malaysia National Cancer Registry Report (MNCR), a higher 
number of breast cancer cases were detected in 2012 to 2016, compared to the previous 
5-years period  (Azizah et al., 2020). For the year 2012 to 2016, breast cancers were 




Malays (31.5%) (Azizah et al., 2020). Comparatively, Malaysian Chinese breast 
cancer incidence rates were lower than the rates from Singaporean Chinese, as well as 
patients from Maori (New Zealand), New South Wales (Australia), Osaka (Japan), 
Seoul (Korea), and Cali (Columbia) (Azizah et al., 2020). Nonetheless, breast cancers 
were the most commonly detected in Malaysian females group regardless the ethnicity, 
with the percentage of 34.6 to 36.8%, and the highest incidence rate was in the 60-64 
age group (Azizah et al., 2020).  
The report also specified that early screening of the female breast cancers in 
the year of 2007 to 2016 detected the highest incidence rate of stage 2 breast cancers, 
followed by stage 3, stage 4 and stage 1 (Azizah et al., 2020). According to a breast 
cancer research organization, cancer stages could be categorized according to sizes (as 
illustrated in Figure 2.1), effects on the lymph nodes, and the metastasis sites (Breast 
Cancer Now Ltd., 2018).  
 
 
Figure 2.1 Stages of breast cancers according to the tumor sizes. Illustration was 





In the male group, 291 cases were identified from 2012 to 2016, which 
apportioned to 135 cases were from the Malay race, 125 cases were from the Chinese 
race, and 21 cases were from the Indian race. (Azizah et al., 2020). The summary also 
listed Selangor as the state with the top detection of breast cancers, and Wilayah 
Persekutuan with the least number of detection (Azizah et al., 2020). 
Furthermore, there are many subtypes of breast cancers clinically, which could 
be classified into several categories, as in Table 2:1 
Table 2:1 Clinical categories of breast cancers 




1) Invasive ductal carcinoma 
2) Invasive lobular carcinoma  
3) Ductal carcinoma in situ (DCIS) 
4) Other (includes tubular carcinoma, medullary 








1) Benign: Adenosis, fibroadenoma, phyllodes-
tumor, and tubular-adenoma 








1) Hormone Receptor Sensitive (HRS), which 
involved estrogen receptor (ER), progesterone 
receptor (PR), and human epidermal growth factor 
receptor 2 (HER2): 
a. Luminal A (ER+ and/or PR+/HER2–),  
b. Luminal B (ER+ and/or PR+/HER2+),  
2) HER2-enriched (ER– and PR–/HER2+), or c-er-
b2 gene overexpression 
3) Triple-negative (ER– and PR–/HER2–), or basal-








Pandit et al. 
(2020) 
 
Correspondingly, preclinical experimental works also involved breast cancer cell lines, 




and MDA-MB-231 human breast cancer cells. Other subtypes of breast cancer cells 
that were scarcely utilized in research are listed in 
Table 2:2. 
 
Table 2:2 Types of breast cancers lines used in pre-clinical studies. 
Cell lines Origin Reference 
4T1  Mouse origin and mimics 
the stage 4 of human 
breast cancer cells 
DuRoss et al. (2019;) J. Liu et al. 
(2019) 
MDA-MB-361  Human origin and 
metastasizes at brain 
Dinkelborg et al. (2019); Shpyleva 
et al. (2011) 
MDA-MB-468  Human origin Altemus et al. (2019); Dinkelborg 
et al. (2019); Peng Liu et al. 
(2016) 
T47D  Ductal carcinoma Dinkelborg et al. (2019); Rollando 
and Prilianti (2018); Shpyleva et 
al. (2011) 
SK-BR-3  Caucasian ethnic Jaeger et al. (2017); Jafarzadeh et 
al. (2018); Peng Liu et al. (2016) 
BT-474  Ductal carcinoma Jaeger et al. (2017); Peng Liu et 
al. (2016) 
BT-549  Ductal carcinoma Altemus et al. (2019); Dinkelborg 
et al. (2019); Shpyleva et al., 
(2011) 
 
Clinically, different cancer cell subtypes would require different treatment 
approaches, specifying the more targeted treatments (IARC, 2014). Generally, the 
primary treatment for breast cancers is chemotherapy, hormone therapy and surgery 
(Ganggayah et al., 2019). Among the breast cancer patients at all hospitals in Kelantan 
(years of 2007 to 2011) and University Malaya Medical Centre (years of 1993 to 
2016), the data recorded that only 19.1% and 49.4% of the patients, respectively, were 
